"Physostigmine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.
| Descriptor ID |
D010830
|
| MeSH Number(s) |
D02.241.081.251.583.682 D03.132.436.545 D03.633.100.473.402.545
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Physostigmine".
Below are MeSH descriptors whose meaning is more specific than "Physostigmine".
This graph shows the total number of publications written about "Physostigmine" by people in this website by year, and whether "Physostigmine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Physostigmine" by people in Profiles.
-
Prophylactic Physostigmine for Extreme and Refractory Adult Emergence Delirium, Aimed at Increasing Patient Safety and Reducing Health Care Workplace Violence: A Case Report. A A Pract. 2020 Apr; 14(6):e01205.
-
Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, a-Synuclein synthesis, interleukin-1? release, and cholinergic action. Antiinflamm Antiallergy Agents Med Chem. 2013; 12(2):117-28.
-
The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther. 2007 Jan; 320(1):386-96.
-
Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide. J Pharmacol Exp Ther. 2006 Aug; 318(2):855-62.
-
Physostigmine for the acute treatment of restless legs syndrome. Anesth Analg. 2005 Sep; 101(3):726-727.
-
An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res. 2005 Jul; 2(3):281-90.
-
Endogenous ouabain-like factor (OLF) secretion is modulated by nicotinic mechanisms in rat adrenocortical cells. Life Sci. 2004 Mar 12; 74(17):2111-28.
-
A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology. 1999 Apr 12; 52(6):1146-52.
-
Cholinergic modulation of oral activity in drug-naive and chronic haloperidol-treated rats. Pharmacol Biochem Behav. 1991 May; 39(1):49-54.